Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Cancer Cell

Volumn 28, Issue 4, 2015, Pages 415-428

  Zhao, Zeguo ^a   Condomines, Maud ^a   van der Stegen, Sjoukje J C ^a   Perna, Fabiana ^a   Kloss, Christopher C ^a   Gunset, Gertrude ^a   Plotkin, Jason ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD137 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GRANZYME B; INTERFERON REGULATORY FACTOR 7; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CONTROL; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL KINETICS; CELL THERAPY; CONTROLLED STUDY; EX VIVO STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; T CELL CULTURE; T LYMPHOCYTE; TUMOR REJECTION; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; KINETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTIGENS, CD137; ANTIGENS, CD19; ANTIGENS, CD28; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON REGULATORY FACTOR-7; INTERFERON-GAMMA; KINETICS; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84944034504     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.09.004     Document Type: Article

References (62)

1. Agarwal P., Raghavan A., Nandiwada S.L., Curtsinger J.M., Bohjanen P.R., Mueller D.L., Mescher M.F. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J. Immunol. 2009, 183:1695-1704.
2. Brentjens R.J., Latouche J.B., Santos E., Marti F., Gong M.C., Lyddane C., King P.D., Larson S., Weiss M., Rivière I., Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 2003, 9:279-286.
3. Brentjens R.J., Santos E., Nikhamin Y., Yeh R., Matsushita M., La Perle K., Quintas-Cardama A., Larson S.M., Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical cancer research 2007, 13:5426-5435.
4. Brentjens R.J., Rivière I., Park J.H., Davila M.L., Wang X., Stefanski J., Taylor C., Yeh R., Bartido S., Borquez-Ojeda O., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
5. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., Varela-Rohena A., Haines K.M., Heitjan D.F., Albelda S.M., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 2009, 106:3360-3365.
6. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 2013, 13:227-242.
7. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272:719-722.
8. Condomines M., Arnason J., Benjamin R., Gunset G., Plotkin J., Sadelain M. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS ONE 2015, 10:e0130518.
9. Curtsinger J.M., Mescher M.F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 2010, 22:333-340.
10. Davila M.L., Brentjens R., Wang X., Rivière I., Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. OncoImmunology 2012, 1:1577-1583.
11. Davila M.L., Riviere I., Wang X., Bartido S., Park J., Curran K., Chung S.S., Stefanski J., Borquez-Ojeda O., Olszewska M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6:224ra25.
12. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208:1989-2003.
13. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 2011, 208:2005-2016.
14. Gade T.P., Hassen W., Santos E., Gunset G., Saudemont A., Gong M.C., Brentjens R., Zhong X.S., Stephan M., Stefanski J., et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005, 65:9080-9088.
15. Gallardo H.F., Tan C., Sadelain M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther. 1997, 4:1115-1119.
16. Golding A., Rosen A., Petri M., Akhter E., Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 2010, 131:107-117.
17. Gong M.C., Latouche J.B., Krause A., Heston W.D., Bander N.H., Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999, 1:123-127.
18. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509-1518.
19. Hervas-Stubbs S., Riezu-Boj J.I., Gonzalez I., Mancheño U., Dubrot J., Azpilicueta A., Gabari I., Palazon A., Aranguren A., Ruiz J., et al. Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur. J. Immunol. 2010, 40:3389-3402.
20. Ho W.Y., Blattman J.N., Dossett M.L., Yee C., Greenberg P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003, 3:431-437.
21. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6:644-658.
22. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
23. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13:95-109.
24. Imai C., Mihara K., Andreansky M., Nicholson I.C., Pui C.H., Geiger T.L., Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
25. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14:36-49.
26. Jaime-Ramirez A.C., Mundy-Bosse B.L., Kondadasula S., Jones N.B., Roda J.M., Mani A., Parihar R., Karpa V., Papenfuss T.L., LaPerle K.M., et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J. Immunol. 2011, 186:3401-3409.
27. Kowolik C.M., Topp M.S., Gonzalez S., Pfeiffer T., Olivares S., Gonzalez N., Smith D.D., Forman S.J., Jensen M.C., Cooper L.J. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006, 66:10995-11004.
28. Lee J.C., Hayman E., Pegram H.J., Santos E., Heller G., Sadelain M., Brentjens R. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011, 71:2871-2881.
29. Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., Cui Y.K., Delbrook C., Feldman S.A., Fry T.J., Orentas R., Sabatino M., Shah N.N., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015, 385:517-528.
30. Lim J.Y., Gerber S.A., Murphy S.P., Lord E.M. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol. Immunother. 2014, 63:259-271.
31. Maher J., Brentjens R.J., Gunset G., Rivière I., Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 2002, 20:70-75.
32. Manabe A., Yi T., Kumagai M., Campana D. Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. I. Cytotoxicity of interferon alpha in acute lymphoblastic leukemia. Leukemia 1993, 7:1990-1995.
33. Marshall H.D., Prince A.L., Berg L.J., Welsh R.M. IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions. J. Immunol. 2010, 185:1419-1428.
34. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371:1507-1517.
35. Mescher M.F., Curtsinger J.M., Agarwal P., Casey K.A., Gerner M., Hammerbeck C.D., Popescu F., Xiao Z. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 2006, 211:81-92.
36. Miller J.F., Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 2015, 27:439-449.
37. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., Samanta M., Lakhal M., Gloss B., Danet-Desnoyers G., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular therapy 2009, 17:1453-1464.
38. Ngiow S.F., von Scheidt B., Akiba H., Yagita H., Teng M.W., Smyth M.J. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011, 71:3540-3551.
39. Nguyen K.B., Watford W.T., Salomon R., Hofmann S.R., Pien G.C., Morinobu A., Gadina M., O'Shea J.J., Biron C.A. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002, 297:2063-2066.
40. Nishikawa H., Kato T., Tawara I., Ikeda H., Kuribayashi K., Allen P.M., Schreiber R.D., Old L.J., Shiku H. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J. Immunol. 2005, 175:4433-4440.
41. Park Y.C., Burkitt V., Villa A.R., Tong L., Wu H. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999, 398:533-538.
42. Ramos C.A., Savoldo B., Dotti G. CD19-CAR trials. Cancer J. 2014, 20:112-118.
43. Rivière I., Brose K., Mulligan R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 1995, 92:6733-6737.
44. Sadelain M. CAR therapy: the CD19 paradigm. J. Clin. Invest. 2015, 125:3392-3400.
45. Sadelain M., Brentjens R., Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 2009, 21:215-223.
46. Saoulli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A., Goldstein M.D., Bangia N., DeBenedette M.A., Mak T.W., Choi Y., Watts T.H. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 1998, 187:1849-1862.
47. Sasai M., Tatematsu M., Oshiumi H., Funami K., Matsumoto M., Hatakeyama S., Seya T. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Mol. Immunol. 2010, 47:1283-1291.
48. Sato M., Hata N., Asagiri M., Nakaya T., Taniguchi T., Tanaka N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 1998, 441:106-110.
49. Shin H.H., Lee E.A., Kim S.J., Kwon B.S., Choi H.S. A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production. FEBS Lett. 2006, 580:1601-1606.
50. Spaapen R.M., Leung M.Y., Fuertes M.B., Kline J.P., Zhang L., Zheng Y., Fu Y.X., Luo X., Cohen K.S., Gajewski T.F. Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature. J. Immunol. 2014, 193:4254-4260.
51. Srivastava S., Koch M.A., Pepper M., Campbell D.J. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 2014, 211:961-974.
52. Stephan M.T., Ponomarev V., Brentjens R.J., Chang A.H., Dobrenkov K.V., Heller G., Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 2007, 13:1440-1449.
53. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
54. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
55. Tammana S., Huang X., Wong M., Milone M.C., Ma L., Levine B.L., June C.H., Wagner J.E., Blazar B.R., Zhou X. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 2010, 21:75-86.
56. Tsukahara T., Ohmine K., Yamamoto C., Uchibori R., Ido H., Teruya T., Urabe M., Mizukami H., Kume A., Nakamura M., et al. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. Biochem. Biophys. Res. Commun. 2013, 438:84-89.
57. van der Stegen S.J., Hamieh M., Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 2015, 14:499-509.
58. Wigginton J.M., Gruys E., Geiselhart L., Subleski J., Komschlies K.L., Park J.W., Wiltrout T.A., Nagashima K., Back T.C., Wiltrout R.H. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 2001, 108:51-62.
59. Yang X., Zhang X., Fu M.L., Weichselbaum R.R., Gajewski T.F., Guo Y., Fu Y.X. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014, 25:37-48.
60. Ysebrant de Lendonck L., Tonon S., Nguyen M., Vandevenne P., Welsby I., Martinet V., Molle C., Charbonnier L.M., Leo O., Goriely S. Interferon regulatory factor 3 controls interleukin-17 expression in CD8 T lymphocytes. Proc. Natl. Acad. Sci. USA 2013, 110:E3189-E3197.
61. Zhao Y., Wang Q.J., Yang S., Kochenderfer J.N., Zheng Z., Zhong X., Sadelain M., Eshhar Z., Rosenberg S.A., Morgan R.A. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 2009, 183:5563-5574.
62. Zhong X.S., Matsushita M., Plotkin J., Riviere I., Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 2010, 18:413-420.